Feagan B G *et al.*, Gastroenterology, Vol. 150, No. 4, Supplement 1, S1266, Abstract 812a, 2016).

Treatment regimens for CD with anti-IL-23p19 antibodies are disclosed in WO 2014/143540 Al and WO 2017/048901 Al.

There remains a need for treatment options for CD that lead to favourable outcomes for patients, for example, in terms of efficacy, safety and/or tolerability of the treatment. In particular, there remains a need for treatment options in the form of dosage regimen of mirikizumab that provides optimal efficacy in the treatment of CD.

SUMMARY

In a first aspect, the present disclosure refers to a use of mirikizumab in the manufacture of a medicament for treating Crohn's Disease (CD) in a patient, wherein

a) three induction doses of the medicament are to be administered to the patient at about 4 week intervals by intravenous infusion, wherein each induction dose comprises about 900 mg of mirikizumab; and

b) maintenance dose(s) of the medicament are to be administered to the patient by subcutaneous injection at about 4 week or about 8 week intervals, wherein the first maintenance dose is to be administered about 4 weeks or about 8 weeks after the last induction dose is administered and wherein each maintenance dose comprises about 200 mg or about 300 mg of mirikizumab,

wherein the CD is moderate to severe CD.

CLAIMS:

1. Use of mirikizumab in the manufacture of a medicament for treating Crohn's Disease (CD) in a patient, wherein

a) three induction doses of the medicament are to be administered to the patient at about 4 week intervals by intravenous infusion, wherein each induction dose comprises about 900 mg of mirikizumab; and

b) maintenance dose(s) of the medicament are to be administered to the patient by subcutaneous injection at about 4 week or about 8 week intervals, wherein the first maintenance dose is to be administered about 4 weeks or about 8 weeks after the last induction dose is administered and wherein each maintenance dose comprises about 200 mg or about 300 mg of mirikizumab,

wherein the CD is moderate to severe CD.

2. The use according to claim 1, wherein the patient is conventional-failed.

3. The use according to claim 1, wherein the patient is biologic-experienced.

4. The use according to claim 1, wherein the patient is biologic-failed.

5. The use according to any of claims 1-4, wherein the induction doses of mirikizumab are for administration to the patient at Week 0, Week 4, and Week 8.

6. The use according to any one of claims 1-5, wherein the first maintenance dose of the medicament is to be administered about 4 weeks after the last induction dose is administered.

7. The use according to any one of claims 1-6, wherein the maintenance doses of the medicament are to be administered at about 8 week intervals.

8. The use according to any one of claims 1-6, wherein the maintenance doses of the medicament are to be administered at about 4 week intervals.

9. The use according to any one of claims 1-8, wherein each maintenance dose of the medicament comprises about 300 mg.

10. The use according to any one of claims 1-8, wherein each maintenance dose of the medicament comprises about 200 mg.